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ABSTRACT
Background: The reduction of hepatitis B virus replication to minimal levels is emerging as key thera-
peutic goal in chronic hepatitis B (CHB).
Objectives: This study aimed to evaluate and compare the efficacies of adefovir (ADV) and entecavir 
(ETV) in CHB.
Patients and Methods: In this prospective study, 100 naïve patients were assigned to treatment with 
ADV (33 HBeAg-positive and 19 HBeAg-negative patients) or ETV (32 HBeAg-positive and 16 HBeAg-
negative patients). The primary efficacy outcome was ALT normalization, reduction in HBV DNA, and 
seroconversion of HBeAg. Second efficacy outcomes included resistance and safety. Comparisons of 
quantitative and qualitative variables between groups were analyzed by student t-test and chi-square 
test (or Fisher’s exact test), respectively.
Results: Among HBeAg-positive patients, ETV was superior to ADV with respect to mean reduction 
in HBV DNA (-7.5 versus -6.3, respectively, at Month 24, p=0.003) and the percentage of those with 
HBV DNA<103 copies/mL at Month 24 [96.9% (31/32) vs. 69.7% (23/33), respectively, p=0.002] and <300 
copies/mL at Month 24 [84.4% (27/32) vs. 54.5% (18/33), respectively, p=0.004]. But, the rates of ALT 
normalization and HBeAg seroconversion between the groups were similar [87.9% (29/33) vs. 96.9% 
(31/32), respectively, p=0.355; and 24.2% (8/33) vs. 25.0% (8/32), respectively, p=0.943]. In HBeAg-negative 
patients who received ETV or ADV, the reduction in HBV DNA (-6.8 versus -5.9, respectively, p=0.192), 
percentage of ALT normalization [100% (16/16) vs. 78.9% (15/19), respectively, p=0.109], HBV DNA<103 
copies/mL [100% (16/16) vs. 89.5% (17/19), respectively, p=0.489], and HBV DNA <300 copies/mL [100% 
(16/16) vs. 84.2% (16/19), respectively, p=0.234] were similar. No ETV- or ADV-associated mutations were 
observed, and both agents were well tolerated.
Conclusions: ETV and ADV are effective therapies for CHB. In HBeAg-positive patients, the efficacy of 
ETV is significantly superior to that of ADV, and in HBeAg-negative patients, the agents effect similar 
biochemical and virological responses.
  Implication for Health policy/practice/research/medical education: 
Authors studied the effects of some oral antiviral medications in treatment of chronic hepatitis B virus. This article is an interesting article for those 
clinicians involved in the management of CHB patients.
  Please cite this paper as:
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Background
More than 400 million individuals worldwide are chronically 
infected with hepatitis B virus (1), and chronic hepatitis B (CHB) 
can progress to cirrhosis, hepatocellular carcinoma (HCC), and 
death (2). Antiviral therapy is used in CHB to minimize liver 
damage and limit disease progression (3). The most significant 
risk factor for the development of cirrhosis or HCC is serum HBV 
DNA level (4, 5), and it appears that the sustained suppression 
of serum HBV DNA replication is essential for impeding or re-
versing disease progression. Nucleoside and nucleotide analogs 
can function as antiviral agents by inhibiting HBV replication 
and competing with the natural nucleotide substrate of DNA 
polymerase, thereby terminating the synthesis of viral DNA (6).
In the last decade, 4 nucleoside and nucleotide analogs (lami-
vudine, adefovir (ADV), entecavir (ETV), and telbivudine) were 
approved for the treatment of CHB in China (7, 8). These agents 
vary  with  respect  to  antiviral  and  clinical  efficacy,  resistance 
profiles, tolerability, and safety. With the introduction of the 
concept of long-term management for CHB (9, 10), the clinical 
challenge is to determine how to use available agents most ef-
fectively to obtain consistent, profound, and long-lasting HBV 
suppression with good safety and convenience in a variety of 
health care settings (11). According to a World Health Organiza-
tion (WHO) estimate, one-third of CHB patients reside in China. 
Recently, some studies have reported that the race or ethnicity 
of patients affects the efficacy of anti-HBV treatment (12-14). Un-
fortunately, few studies have been performed in Chinese CHB 28
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patients.  It  is  unknown  whether  treatment  with  nucleoside 
analogs in Chinese CHB patients differs compared with patients 
from other regions.ADV is an oral acyclic nucleotide analog with 
potent and specific effects against HBV infection. With the avail-
ability of tenofovir (15), ADV has begun to be withdrawn from 
certain regions. Due to its lengthy time to market and high cost, 
however, the likelihood of obtaining tenofovir remains distant 
for the majority of CHB patients. In China, ADV remains widely 
used as a first-line antiviral agent. Recently, HBeAg-negative sta-
tus and low baseline serum HBV DNA levels have been reported 
to be associated with virological response in ADV-treated CHB 
patients (16).
Objectives
This study compared the efficacy and safety of long-term treat-
ment with ADV and ETV in HBeAg-positive and HBeAg-negative 
CHB patients.
Patients and Methods
Patients
Outpatients from West China Hospital with chronic hepati-
tis B, aged 18 years or older, were screened and included in this 
study, per the following criteria: positive reading for hepatitis 
B  surface  antigen  (HBsAg)  for  at  least  6  months;  serum  HBV 
DNA load above 1000 copies/ml at baseline; and meeting the 
general indications for antiviral therapy, as recommended by 
the Chinese Society of Hepatology.The exclusion criteria were: 
presence of serum antibodies against hepatitis C virus (HCV) or 
human immunodeficiency virus (HIV); a course of preantiviral 
agent therapy (nucleoside analogs or interferon) for more than 
3 months; breastfeeding, pregnancy, or inadequate contracep-
tive measures; substance abuse in the previous 2 years; other ac-
quired or inherited causes of liver disease; serious concomitant 
disease; and advanced liver disease (including decompensated 
cirrhosis with ascites, severe hepatitis, and hepatic carcinoma).
Study design
This prospective, controlled study evaluated and compared 
the efficacy of ADV and ETV in Chinese CHB patients. Patients 
were administered 10 mg ADV (GlaxoSmithKline) or 0.5 mg ETV 
(Bristol-Myers Squibb) daily according to individual choice, and 
they were followed up in the outpatient clinic of West China 
Hospital. Clinical data were collected at baseline and every 3 
months after treatment. The primary efficacy outcome was ALT 
normalization, reduction in HBV DNA, and seroconversion of 
HBeAg. Second efficacy outcomes included resistance and safety.
This study was approved by West China Hospital’s institutional 
review board and was conducted per the 1975 Declaration of Hel-
sinki. All patients signed informed consent forms before their 
inclusion in this study.
Serum assay 
HBeAg and serum HBV DNA were measured by ELISA (Intec 
Stone,  China)  and  the  PCR-based  Cobas  Amplicor  HBV  Moni-
tor Test (Roche Diagnostics, China) per the manufacturer’s in-
structions, respectively. Serum ALT, creatinine (Cr), and creatine 
kinase (CK) were measured on an automatic biochemistry an-
alyzer (Olympus AU5400, Japan) according to standard labora-
tory procedures. HBV mutations that were associated with resis-
tance to ADV (rtA181V/T and rtN236T) and ETV (rtI169T, rtL180M, 
rtT184G, rtS202I, rtM204V/I, and rtM250V) were analyzed by PCR 
pyrosequencing assay if virological rebound (defined as a con-
firmed increase in HBV DNA levels by at least 1 log-copy per mil-
liliter from the nadir value, based on PCR) occurred.
Statistical analysis
Quantitative variables were expressed as mean values; cate-
gorical variables were expressed as counts and percentages; and 
HBV DNA levels were log-transformed. Comparisons between 
groups of quantitative and qualitative variables were analyzed 
by student t-test and chi-square test (or Fisher’s exact test), re-
spectively. A p-value of less than 0.05 (two-tailed) indicated a sig-
nificant difference. All statistical analyses were performed using 
SPSS, version 13.0 (SPSS Inc., Chicago, IL).
Results
Characteristics of the study patients
A  total  of  100  patients  from  West  China  Hospital,  Sichuan 
University were enrolled in the study between June 2007 and 
April 2008; 52 patients were given ADV, and 48 patients were ad-
ministered ETV. In the ADV group, there were 33 HBeAg-positive 
patients and 19 HBeAg-negative patients at baseline. In the ETV 
group,  there  were  32  HBeAg-positive  patients  and  16  HBeAg-
negative patients at baseline. The demographics and disease pa-
rameters in HBeAg-positive (Table 1) and HBeAg-negative (Table 
1) patients were well matched between groups at baseline. No 
  
Table 1. Baseline characteristics of HBeAg positive and negative patients
a ADV: adefovir
b ETV: entecavir
Characteristic   ADV a                                       ETV b                 p-value
                         Positive (N=33)  Negative (N=19)             Positive (N=32)   Negative (N=16)           Positive  Negative
Male      24 (72.7)    13 (68.4)               23 (71.9)     14 (87.5)             0.939   0.244
No. (%)     
Age (Mean±SD, year)   34.18    36.58               36.81      39.44             0.108   0.313
BMI (kg/m2)     22.58    21.35               22.24                          23.25             0.687                       0.096
ALT (IU/L)     174.73    160.0               208.75     159.3             0.247                       0.988
HBV DNA    7.91    6.44               7.98                           6.76                                 0.835                        0.575
(log 10 copies/ml)
Smoke     13 (39.4)    6 (31.6)               10 (31.3)    4 (25.0)             0.492   0.723 
No. (%) 
Drink     13 (39.4)    5 (26.3)               13 (40.6)                         4 (25.0)                                 0.919                         1.000
No. (%) 29
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Figure 2. Serum reduction in HBV DNA levels from baseline. Panel A shows the reduction in HBV DNA levels from baseline to Month 24 in HBeAg-positive patients. Panel B 
shows the reduction in HBV DNA levels from baseline to Month 24 in HBeAg-negative patients
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Figure 1. Serum ALT normalization in HBeAg-positive and HBeAg-negative patients from baseline to Month 24. Panel A- rate of ALT normalization in HBeAg-positive pa-
tients receiving ETV or ADV; the difference in ALT normalization was not significant between groups from Months 6 to 24 after treatment. Panel B- rate of ALT normalization 
in HBeAg-negative patients receiving ETV or ADV; the difference in ALT normalization was not significant between groups
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patient discontinued treatment due to poor efficacy or disease 
progression.
Biochemical response
Serum ALT levels declined in both treatment groups. At 6, 12, 
and 24 months, normal ALT was achieved in 23 of 33 (69.7%), 25 
of 33 (75.8%), and 29 of 33 (87.9%) HBeAg-positive patients in the 
ADV and in 20 of 32 (62.5%), 26 of 32 (81.3%), and 31 of 32 (96.9%) 
HBeAg-positive patients in the ETV group, respectively (Figure 
1A). In HBeAg-negative patients at 6, 12, and 24 months, normal 
ALT was attained in 14 of 19 (73.7%), 14 of 19 (73.7%), and 15 of 19 
(78.9%) ADV-treated cases and in 13 of 16 (81.3%), 14 of 16 (87.5%), 
and 16 of 16 (100%) patients who were given ETV, respectively (Fig-
ure 1B). The difference in ALT normalization between groups was 
not significant in HBeAg-positive or HBeAg negative patients.
Virological response
In HBeAg-positive patients, the reduction in serum HBV DNA 
levels from baseline during the observation period was signifi-
cantly greater with ETV compared with ADV (Figure 2A); at 24 
months, serum HBV DNA levels declined by a mean of 5.6 and 
6.0 log10 copies⁄mL with ADV and ETV, respectively (P=0.008). At 
6, 12, and 24 months, HBV DNA < 103 copies/ml was achieved in 5 
of 33 (15.2%), 11 of 33 (33.3%), and 23 of 33 (69.7%) patients with ADV 
and in 17 of 32 (53.1%), 23 of 32 (71.9%), and 31 of 32 (96.9%) patients 
with ETV, respectively (P = 0.001, P = 0.002, P = 0.003, respec-
Figure 4. Percentage of HBeAg-positive patients with HBeAg seroconversion in 
the ADV and ETV groups. The differences between groups were not significant at 
Month 12 or 24.
Figure 3. The percentage of those who obtained a virological response between ADV- and ETV-treated HBeAg-positive and HBeAg-negative patients.
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tively , between treatment groups) (Figure 3A). At 6, 12, and 24 
months, HBV DNA < 300 copies/ml was achieved in 2 of 33 (6.1%), 
9 of 33 (27.3%), and 18 of 33 (54.5%) patients with ADV and in 9 of 
32 (28.1%), 20 of 32 (62.5%), and 27 of 32 (84.4%) patients with ETV, 
respectively (P = 0.018, P = 0.004, P = 0.009, respectively, between 
treatment groups) (Figure 3B).In HBeAg-negative patients, the 
reduction in serum HBV DNA levels from baseline did not differ 
between ADV and ETV treatments (Figure 2B); at 24 months, se-
rum HBV DNA levels fell by a mean of 5.9 and 6.8 log10 copies⁄mL 
with ADV and ETV, respectively (P=0.192). At 6, 12 and 24 months, 
HBV DNA < 103 copies/ml was achieved in 9 of 19 (47.4%), 14 of 19 
(73.7%), and 17 of 19 (89.5%) patients with ADV and in 12 of 16 (75%), 
14 of 16 (87.5%), and 16 of 16 (100%) patients with ETV, respectively 
(P = 0.096, P = 0.309, P = 0.489, respectively, between treatment 
groups) (Figure 3C). At 6, 12, and 24 months, HBV DNA < 300 cop-
ies/ml was achieved in 4 of 19 (21.1%), 12 of 19 (63.2%), and 16 of 
19 (84.2%) patients with ADV and in 9 of 16 (56.3%), 12 of 16 (75%), 
and 16 of 16 (100%) patients with ETV, respectively (P = 0.032, P 
= 0.452, and P = 0.234, respectively, between treatment groups) 
(Figure 3D).  
HBeAg response
Two of 33 (6.1%) and 3 of 32 (9.4%) HBeAg-positive patients ex-
perienced HBeAg seroconversion at Month 12 with ADV and ETV, 
respectively  (P=0.672  between  groups)  (Figure  4).  The  overall 
HBeAg seroconversion rates in the groups continued to rise dur-
ing the study period. At Month 24, the cumulative rate of HBeAg 
seroconversion occurred in 8 of 33 (24.2%) patients with ADV 
compared with 8 of 32 (25%) patients with ETV (P=0.943).
Breakthrough and resistance
Viral breakthrough was not observed in any patients during 
the 2-year observation period, and HBV mutations were not ana-
lyzed in the first 2 years of treatment.
Safety
Four patients who received ADV had slightly increased serum 
creatinine levels from baseline (less than 44.2 µmol per liter), 
but there were no discontinuations due to this adverse event. In 
ETV recipients, no benign or malignant lesions in the lung were 
detected. Elevations in ALT were observed less frequently in the 
ETV group than in the ADV group. ALT flares were observed in 
3 patients who received ETV and 10 ADV-treated patients. In the 
ETV group, all ALT flares in the 2 year treatment period were as-
sociated with alcohol consumption. In the ADV group, 6 of the 
ALT flares were associated with alcohol consumption and 4 were 
associated with HBV DNA flares. In the ETV group, 1 patient devel-
oped a small hepatocellular carcinoma at Month 15 and received 
immediate surgical intervention; ETV treatment was never dis-
continued.
Discussion
The treatment options for CHB are limited. The principal goals 
of anti-HBV treatment are to suppress HBV DNA, normalize ALT 
levels, and reduce liver necroinflammation. In this study, both 
ADV and ETV were efficacious in among positive- and negative-
HBeAg CHB patients with regard to biochemical and virological 
responses. In HBeAg-positive patients, ETV was significantly su-
perior to ADV in terms of virological response, which is consis-
tent with other studies of ETV that have demonstrated reduced 
HBV  DNA  levels  (17-20),  attributed  to  its  suppression  of  HBV 
replication.Based on the nephrotoxicity, the dose of ADV was ad-
justed from 30 mg to 10 mg for CHB patients, but Vitro, this dose 
adjustment weakened the antiviral activity of ADV, and clinical 
studies have reported that the virological response of ADV is less 
robust than that of other anti-HBV agents. In this study, the viro-
logical response of ADV in HBeAg-positive patients was signifi-
cantly lower than that of ETV, but in HBeAg-negative patients, 
ADV had similar biochemical and virological responses as ETV.
In a separate analysis, the percentage of ADV-treated HBeAg-pos-
itive and HBeAg-negative patients with HBV <300 copies/mL was 
54.5% and 84.2%, respectively. This result suggests that the effica-
cy of ADV differs in HBeAg-negative and HBeAg-positive patients. 
Further, other nucleoside analogs have had high therapeutic ef-
ficacy in HBeAg-negative patients (21-23).But, the exact mecha-
nism that underlies the effect of baseline negative HBeAg status 
on virological response remains unknown. In the ADV group, 
the mean baseline HBV DNA level was 6.44 and 7.91 log10 copies/
mL in HBeAg-negative and HBeAg-positive patients, respectively; 
thus, lower baseline HBV DNA levels may contribute to a more 
robust virological response for ADV in HBeAg-negative patients. 
Some studies have suggested that baseline HBV DNA level is an 
independent predictor of long-term virological response (24, 
25).In this study, genotypic substitutions in polymerase-reverse 
transcriptase were detected only in patients with viral break-
through. During the limited 2-year observation period, no viral 
breakthrough was observe in ADV- or ETV-treated patients; thus, 
the rates of viral breakthrough and resistance with ADV that we 
observed are better than those of other reports (26, 27). How-
ever,  resistance  patterns  with  long-term  treatment  were  not 
determined in this study, and the resistance rate to ADV might 
increase significantly during subsequent treatments. Thus, we 
will continue to monitor all of our patients closely.HBeAg loss 
or seroconversion indicates durable immune control of hepa-
titis B virus. But, in this study, the percentage of patients who 
experienced seroconversion of HBeAg was less than 30% in both 
groups. Due to the absence of HBeAg loss or seroconversion, 
long-term treatment is often required to maintain viral sup-
pression, and the treatment strategy for such patients should be 
optimized. Substituting or adding an antiviral agent that effects 
higher seroconversion rates is a warranted option. The data on 
adverse events are consistent with previous findings. Severe re-
nal impairment was not observed in patients who received ADV. 
Further, 4 of the 52 ADV recipients had slightly increased serum 
creatinine levels from baseline; they were monitored closely, 
and the levels normalized without any additional treatment. 
In this study, flares of ALT were more frequent in patients who 
consumed alcohol. Health education must be stressed for pa-
tients with poor compliance. After reviewing the family history 
of a patient who developed HCC in the ETV group, we noted that 
his father and brother died from HBV-associated HCC. Thus, pa-
tients with a family history of HCC should be monitored closely.
In this study, many observations were difficult to explain. For 
example, why were the dynamics of the viral response similar 
in only some ADV-treated and ETV-treated patients? Alterations 
in drug absorption and metabolism of ADV in patients should 
be considered. One could argue that these patients, with HBV 
DNA> 103 copies/mL, simply need an adjustment of treatment 
strategies to overcome the weakened responsiveness, such as 
switching to or adding another potent anti-HBV agent that does 
not have crossresistance to ADV. Our study complements the an-
tiviral data on nucleoside and nucleotide analogs. ETV should 32
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be recommended for both HBeAg-positive and HBeAg-negative 
patients. However, for naïve chronic hepatitis B patients who 
are HBeAg-negative and have lower HBV DNA levels at baseline, 
ADV should also be considered. Adefovir and entecavir were ef-
fective as CHB treatments. In HBeAg-positive patients, the effi-
cacy of ETV was significantly superior to that of ADV, but similar 
biochemical and virological responses were observed with both 
agents in HBeAg-negative patients. Thus, adefovir can be consid-
ered for HBeAg-negative patients with lower HBV DNA levels at 
baseline.
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